Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psychiatry Advisor
A network meta-analysis of 24 antipsychotics across 78,193 patients with schizophrenia identified clozapine, amisulpride, olanzapine, and risperidone as most effective, with small-to-medium efficacy differences and notable variation in tolerability profiles.
Psychiatry April 29th 2026
MedCentral
The new chemical entity is an atypical antipsychotic and the active metabolite of iloperidone (Fanapt). Its ability to cross the blood-brain barrier likely contributes to iloperidone’s clinical effects.
Psychiatry March 4th 2026
Psychiatrist.com
“For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine.” — Leucht et al, J Clin Psychiatry 2026
Psychiatry February 18th 2026
Psych Congress Network
“Evenamide has the potential to treat the symptoms of schizophrenia more broadly, addressing also those poorly managed by the currently available antipsychotics.” — Ravi Anand, MD, Therapeutic Advances in Psychopharmacology
Clozapine did not show superior efficacy compared to second-generation antipsychotics in treatment-resistant schizophrenia.
Clinical Pharmacology May 28th 2025
Psych Congress NP Institute
Expert psychiatric nurse practitioners stress the importance of familiarity with product inserts for each long-acting injectable antipsychotic to effectively manage missed doses in schizophrenia treatment.
Neurology August 27th 2024